Investigational drug · Phase 2
Secretome
Also called: Conditioned, Umbilical Cord Mesenchymal Stem Cells derived Conditioned
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
61
Any phase or sponsor naming "Secretome"
First trial start
2021
Oct 13, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Secretome", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Respiratory Distress Syndrome
- Androgenetic Alopecia
- Ischemic Stroke
- Cerebral Palsy
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic · Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Secretome" as an intervention, largest first.
- MSC Secretome and rTMS for Motor Recovery After Subacute Ischemic StrokePivotal-lookingNot yet recruiting
Jumraini TammasseAcademic, hospital or other
NCT07874269 · 205 participants (planned) · Start Nov 2026 · Primary completion Jul 2027
Drug: Mesenchymal Stem Cell-Derived Secretome; 0.9% Sodium Chloride Placebo · For: Ischemic Stroke
Sites: Makassar, Indonesia
- Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental StudyPivotal-lookingNot yet recruiting
Yohanes Firmansyah, dr, MH, MMAcademic, hospital or other
NCT07509242 · 150 participants (planned) · Start Mar 18, 2026 · Primary completion Jan 18, 2027
Drug: NB-UVB alone · For: Vitiligo
Sites: Tangerang, Indonesia
- Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCEDPivotal-lookingTerminated
Combangio, IncIndustry
NCT05727878 · 103 participants · Start Feb 7, 2023 · Primary completion Sep 29, 2025
Drug: KPI-012; KPI-012 Vehicle · For: Persistent Corneal Epithelial Defect
Sites: Dothan, Alabama; Irvine, California; La Jolla, California · 46 sites in all
- Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma TherapyStatus unknown
Dr.dr.Irma Bernadette, SpKK (K)Academic, hospital or other
NCT06516419 · 90 participants (planned) · Start Feb 13, 2024 · Primary completion Mar 30, 2025
Drug: Concentrated secretome Injection 2mL; Tranexamic acid injection and 1 more · For: Melasma
Sites: Jakarta Pusat, Indonesia · 2 sites in all
Lomonosov Moscow State University Medical Research and Educational CenterAcademic, hospital or other
NCT06869863 · 80 participants (planned) · Start Nov 26, 2024 · Primary completion Dec 2025
Drug: Medicinal product MediReg® (Human Mesenchymal Stromal Cell Secretome), lyophilizate for preparation of solution for injection in patients with severe spermatogenesis disorders · For: Azoospermia, Nonobstructive; Teratospermia; Oligospermia and 1 more
Sites: Moscow, Russia
Jumraini TammasseAcademic, hospital or other
NCT07731087 · 70 participants (planned) · Start Jul 9, 2026 · Primary completion Nov 2026
Drug: Umbilical Cord Mesenchymal Stem Cell-Derived Secretome · For: Ischemic Stroke; Post-Stroke Cognitive Impairment
Sites: Makassar, Indonesia
The Foundation for Orthopaedics and Regenerative MedicineAcademic, hospital or other
NCT07105371 · 70 participants · Start Jul 14, 2024 · Primary completion Oct 1, 2026
Drug: Exosome Secretome · For: Motor Disorders
Sites: Naples, Florida; Athens, Greece
- The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne TreatmentNot yet recruiting
Universitas PadjadjaranAcademic, hospital or other
NCT06925386 · 64 participants (planned) · Start May 1, 2025 · Primary completion Dec 31, 2025
Drug: Standard therapy; Secretome · For: Acne Vulgaris
Sites: Denpasar, Indonesia
- Effect of PMSCs and Their Secretome for the Treatment of GvHDPivotal-lookingCompleted
Tabriz University of Medical SciencesAcademic, hospital or other
NCT06469411 · 60 participants · Start Jan 1, 2023 · Primary completion Jun 30, 2023
Drug: Secretome (set of substances released from the cell to its surroundings) of mesenchymal stem cells retrieved from the placenta (containing 400 microgram protein/ milliliter) · For: GVHD
Sites: Tabriz, Iran
- Hair Regeneration in Androgenetic AlopeciaStatus unknown
Dr. dr. Lili Legiawati, SpKK(K)Academic, hospital or other
NCT06066827 · 60 participants · Start Aug 14, 2023 · Primary completion Nov 30, 2023
Drug: Minoxidil Topical · For: Androgenetic Alopecia
Sites: Jakarta Pusat, Indonesia · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Quantitative screening of Legionella pneumophila in preconcentrated water samples using a portable SERS lateral-flow immunoassay.
Quintero-Campos P, Bittinger SC, Chavarri-Urraca K, et al. · Talanta 2027
- Occurrence, persistence and pathogenic potential of Bacillus cereus sensu lato strains isolated during processing of two plant-based desserts.
Zanetti M, Guinebretière MH, Oriol S, et al. · Food Microbiol 2027
- Reprogramming pathological secretory phenotype of chondrocytes inhibits neurovascular invasion for osteoarthritis treatment.
Yuan X, Xiao Y, Chen C, et al. · Bioact Mater 2027
- Dynamic tensile conditioning of mesenchymal stem cell-laden auxetic scaffolds for enhanced YAP-dependent miR-30 enrichment in extracellular vesicles for pulmonary fibrosis therapy.
Chen JX, Ho CC, Lin YH, et al. · Biomaterials 2027
- Matrix conditioning and magnetic bead target transfer for fluorescence aptamer-CRISPR/Cas12a detection of kanamycin in river water.
Yang T, Yu X, Wu J · Talanta 2027
- Layer-by-layer nanoparticle outer polyelectrolyte impacts protein corona formation.
Dacoba TG, Douglas-Green SA, Murthy B, et al. · Biomaterials 2027
Also in development for Acute Respiratory Distress Syndrome
- STSA-1002Phase 32 trials
Staidson (Beijing) Biopharmaceuticals Co., Ltd · Acute Respiratory Distress Syndrome (ARDS), Acute Respiratory Distress Syndrome
- UC-MSCRY_SW01 cell, Human umbilical cord mesenchymal stem cellsPhase 28 trials
Jiangsu Renocell Biotech Company · Acute Respiratory Distress Syndrome, Lupus Nephritis, Spinocerebellar Ataxia Type 1
- AtibuclimabIC14Phase 24 trials
Implicit Bioscience · Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury
- paridiprubartPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- rhu-pGSNrecombinant human gelsolin, Recombinant human plasma gelsolin pre-exposurePhase 22 trials
BioAegis Therapeutics Inc. · Acute Respiratory Distress Syndrome, Infections, Decompression Sickness
- vilobelimabPhase 22 trials
PPD Development, LP · Acute Respiratory Distress Syndrome (ARDS), ARDS, ARDS (Acute Respiratory Distress Syndrome)
- AV-001Phase 21 trial
Vasomune Therapeutics, Inc. · Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.